Health● Low44m ago · Nov 10, 2026, 12:51 AM
Trevi outlines non-IPF-ILD Phase II start in Q1 2027 as cash runway extends into 2030
GlobeAlert Desk · curated from Seeking Alpha Tech · global
Trevi has outlined plans to start non-IPF-ILD Phase II trials in Q1 2027, with its cash runway extending into 2030. This provides an update on the company's drug development pipeline and financial outlook.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.
GlobeAlert context
What the desk knows about this story
Threat level
0 Low
Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.
Sources
1 publisher
Single-source so far. Treat details as unconfirmed until more publishers report.
Category
Health
Not flagged as developing.
More in Health
Health51m agoGLP-1s must now include warning for potential increased risk of vision loss, FDA announcesCBS NewsHealth1h agoFDA warns of rare vision-loss side effect from GLP-1 drugsCBS NewsHealth1h agoVeterans Day campaign aims to erase $35M in medical debt for nation heroesmyfox28columbus.com · United StatesHealth4h agoFDA warns of rare ‘eye stroke’ risk from GLP-1 drugsThe Hill